Susan Mahony Sells 300 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Susan Mahony sold 300 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total transaction of $71,163.00. Following the completion of the transaction, the director owned 1,129 shares of the company’s stock, valued at $267,810.09. This trade represents a 20.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Axsome Therapeutics Trading Up 3.0%

Shares of AXSM stock opened at $253.77 on Friday. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. The stock has a market capitalization of $13.06 billion, a P/E ratio of -68.03 and a beta of 0.61. The company has a 50 day moving average price of $209.27 and a 200 day moving average price of $181.43. Axsome Therapeutics, Inc. has a fifty-two week low of $96.09 and a fifty-two week high of $257.44.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The business had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business’s quarterly revenue was up 57.4% compared to the same quarter last year. Equities research analysts predict that Axsome Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on AXSM shares. Morgan Stanley upgraded shares of Axsome Therapeutics from a “reduce” rating to an “overweight” rating in a research note on Thursday. Royal Bank Of Canada lifted their price target on shares of Axsome Therapeutics from $242.00 to $302.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Guggenheim lifted their price target on shares of Axsome Therapeutics from $245.00 to $260.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Friday, May 1st. Finally, UBS Group lifted their price target on shares of Axsome Therapeutics from $251.00 to $259.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $256.79.

Institutional Trading of Axsome Therapeutics

Institutional investors have recently modified their holdings of the stock. Kemnay Advisory Services Inc. purchased a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $31,000. Hollencrest Capital Management lifted its position in shares of Axsome Therapeutics by 400.0% during the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after buying an additional 160 shares during the last quarter. Ameriflex Group Inc. purchased a new stake in shares of Axsome Therapeutics during the 4th quarter worth approximately $37,000. GAMMA Investing LLC lifted its position in shares of Axsome Therapeutics by 65.4% during the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock worth $49,000 after buying an additional 106 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Axsome Therapeutics by 602.6% during the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company’s stock worth $50,000 after buying an additional 235 shares during the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.